The Medicines Company and RNA biotech partner Alnylam have set out a new, large late-stage test for their next-gen anticholesterol candidate inclisiran, which…

AstraZeneca has taken another step toward the completion of its new headquarters and R&D hub in Cambridge, U.K.

Amgen has firmed up its lead in the race to bring the first CGRP inhibitor to market for migraine after presenting positive results from its two phase 3 trials.

Circassia CEO Steve Harris has defended the running of the company’s allergy trials, stating nothing could have been done better.

It’s been a torrid few weeks for pressured OncoMed with trial woes compounded by partners walking away. Now, after hinting at cuts earlier this month, the…

After Jefferies analyst Biren Amin said last night that he thought Novartis would be presenting its midstage CAR-T blood cancer data from Juliet at a Swiss…

Daniel Teper has stepped down immediately as CEO of New York biotech Immune Pharma as he looks to head up its new oncology spinoff.

French biotech Genfit, a leader in the race to sell a new med for fatty liver disease, said in its financials that it will delay its phase 3 NASH trial in…

Fierce 15 company NGM Bio says it met its primary endpoint of reducing liver fat in NASH patients, with hints of antifibrotic activity, as the small biotech…

R&D